Amyloid and tau pathological accumulation should be considered for Alzheimer's disease (AD) definition and before subjects' enrollment in disease-modifying trials. Although age, APOEε4, and sex influence cerebrospinal fluid (CSF) biomarker levels, none of these variables are considered by current normality/abnormality cutoffs. Using baseline CSF data from 2 independent cohorts (PharmaCOG/European Alzheimer's Disease Neuroimaging Initiative and Alzheimer's Disease Neuroimaging Initiative), we investigated the effect of age, APOEε4 status, and sex on CSF Aβ42/P-tau distribution and cutoff extraction by applying mixture models with covariates. The Aβ42/P-tau distribution revealed the presence of 3 subgroups (AD-like, intermediate, control-like) and 2 cutoffs. The identification of the intermediate subgroup and of the higher cutoff was APOEε4 dependent in both cohorts. APOE-specific classification (higher cutoff for APOEε4+, lower cutoff for APOEε4-) showed higher diagnostic accuracy in identifying MCI due to AD compared to single Aβ42 and Aβ42/P-tau cutoffs. APOEε4 influences amyloid and tau CSF markers and AD progression in MCI patients supporting i) the use of APOE-specific cutoffs to identify MCI due to AD and ii) the utility of considering APOE genotype for early AD diagnosis. © 2020 Elsevier Inc. All rights reserved.

CSF cutoffs for MCI due to AD depend on APOEε4 carrier status / Marizzoni, M.; Ferrari, C.; Babiloni, C.; Albani, D.; Barkhof, F.; Cavaliere, L.; Didic, M.; Forloni, G.; Fusco, F.; Galluzzi, S.; Hensch, T.; Jovicich, J.; Marra, C.; Molinuevo, J. L.; Nobili, F.; Parnetti, L.; Payoux, P.; Ranjeva, J. -P.; Ribaldi, F.; Rolandi, E.; Rossini, P. M.; Salvatore, M.; Soricelli, A.; Tsolaki, M.; Visser, P. J.; Wiltfang, J.; Richardson, J. C.; Bordet, R.; Blin, O.; Frisoni, G. B.. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 89:(2020), pp. 55-62. [10.1016/j.neurobiolaging.2019.12.019]

CSF cutoffs for MCI due to AD depend on APOEε4 carrier status

Ferrari C.
Secondo
;
Fusco F.;Jovicich J.;
2020-01-01

Abstract

Amyloid and tau pathological accumulation should be considered for Alzheimer's disease (AD) definition and before subjects' enrollment in disease-modifying trials. Although age, APOEε4, and sex influence cerebrospinal fluid (CSF) biomarker levels, none of these variables are considered by current normality/abnormality cutoffs. Using baseline CSF data from 2 independent cohorts (PharmaCOG/European Alzheimer's Disease Neuroimaging Initiative and Alzheimer's Disease Neuroimaging Initiative), we investigated the effect of age, APOEε4 status, and sex on CSF Aβ42/P-tau distribution and cutoff extraction by applying mixture models with covariates. The Aβ42/P-tau distribution revealed the presence of 3 subgroups (AD-like, intermediate, control-like) and 2 cutoffs. The identification of the intermediate subgroup and of the higher cutoff was APOEε4 dependent in both cohorts. APOE-specific classification (higher cutoff for APOEε4+, lower cutoff for APOEε4-) showed higher diagnostic accuracy in identifying MCI due to AD compared to single Aβ42 and Aβ42/P-tau cutoffs. APOEε4 influences amyloid and tau CSF markers and AD progression in MCI patients supporting i) the use of APOE-specific cutoffs to identify MCI due to AD and ii) the utility of considering APOE genotype for early AD diagnosis. © 2020 Elsevier Inc. All rights reserved.
2020
Marizzoni, M.; Ferrari, C.; Babiloni, C.; Albani, D.; Barkhof, F.; Cavaliere, L.; Didic, M.; Forloni, G.; Fusco, F.; Galluzzi, S.; Hensch, T.; Jovicic...espandi
CSF cutoffs for MCI due to AD depend on APOEε4 carrier status / Marizzoni, M.; Ferrari, C.; Babiloni, C.; Albani, D.; Barkhof, F.; Cavaliere, L.; Didic, M.; Forloni, G.; Fusco, F.; Galluzzi, S.; Hensch, T.; Jovicich, J.; Marra, C.; Molinuevo, J. L.; Nobili, F.; Parnetti, L.; Payoux, P.; Ranjeva, J. -P.; Ribaldi, F.; Rolandi, E.; Rossini, P. M.; Salvatore, M.; Soricelli, A.; Tsolaki, M.; Visser, P. J.; Wiltfang, J.; Richardson, J. C.; Bordet, R.; Blin, O.; Frisoni, G. B.. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 89:(2020), pp. 55-62. [10.1016/j.neurobiolaging.2019.12.019]
File in questo prodotto:
File Dimensione Formato  
marizzoni_NBA_2019.pdf

Open Access dal 31/12/2020

Tipologia: Post-print referato (Refereed author’s manuscript)
Licenza: Creative commons
Dimensione 839.9 kB
Formato Adobe PDF
839.9 kB Adobe PDF Visualizza/Apri
1-s2.0-S0197458019304488-main.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 961.31 kB
Formato Adobe PDF
961.31 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/282136
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact